The historical rank and industry rank for Gyre Therapeutics's Gross Margin % or its related term are showing as below:
GYRE'
s Gross Margin % Range Over the Past 10 Years
Min: 95.31 Med: 95.51 Max: 95.91
Current: 95.91
During the past 3 years, the highestGross Margin % of Gyre Therapeutics was 95.91%. The lowest was 95.31%. And the median was 95.51%.
GYRE's Gross Margin % is ranked better than 94.35% of 743
companies
in the Biotechnology industry
Industry Median: 59.4
vs GYRE: 95.91
Gyre Therapeutics had a gross margin of 95.91% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Gyre Therapeutics was 0.00% per year.
Gyre Therapeutics Gross Margin % Historical Data
The historical data trend for Gyre Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Gyre Therapeutics Gross Margin % Chart
Gyre Therapeutics Annual Data
Trend
Dec21
Dec22
Dec23
Gross Margin %
95.51
95.31
95.91
Gyre Therapeutics Semi-Annual Data
Dec21
Dec22
Dec23
Gross Margin %
95.51
95.31
95.91
Competitive Comparison of Gyre Therapeutics's Gross Margin %
For the Biotechnology subindustry, Gyre Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Gyre Therapeutics had a gross margin of 95.91% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Gyre Therapeutics Gross Margin % Related Terms
Thank you for viewing the detailed overview of Gyre Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Gyre Therapeutics (Gyre Therapeutics) Business Description
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GYRE has been successfully added to your